Delivering Silence

Using RNA viruses to silence genes could optimize tissue targeting while reducing toxicity.

By | March 1, 2012

Since the discovery of RNA interference almost 15 years ago, researchers have tried to devise effective ways to get these short gene-silencing transcripts inside cells. But techniques for in vivo delivery have fallen short. For therapies that require long-term gene knockdown, DNA viruses that insert the microRNA (miRNA) genes into the target cell's genome were the best bet. But that approach produced large numbers of miRNAs, which overloaded the miRNA-processing proteins in the nucleus and resulted in cellular toxicity. For short-term therapies, mature miRNAs encapsulated in liposomes or conjugated to cholesterol were used, but they have been difficult to target to a specific cell type.

Benjamin tenOever, a virologist at Mount Sinai School of Medicine in New York City, tried an unusual work-around: cytoplasmic RNA viruses. Researchers had assumed that RNA viruses wouldn't do the trick because the miRNA transcript never enters the nucleus, and thus couldn't be processed appropriately. But tenOever engineered vesicular stomatitis virus (VSV), an RNA virus, to produce miRNAs, which were processed in the cytosol. Lung cells from mice infected with the VSV vector showed silencing of their target gene. The cytoplasmic miRNA pathway is yet to be elucidated, says tenOever, but "regardless of how it works, it does work, and it works in vivo."

The ideal application of such short-term knockdown is in cancer therapy, tenOever says, where modulation of oncogenic proteins is only necessary while the cancer cells live. (Mol Ther, doi: 10.1038/mt.2011.244, 2011.) .

DNA VIRUS indefinite 10,000s very toxic precise cell type yes
SYNTHETIC miRNA hours–days 1-10s nontoxic organ specific no
RNA VIRUS hours–1 week 100s–1000s nontoxic precise cell type no



Add a Comment

Avatar of: You



Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. UC Berkeley Receives CRISPR Patent in Europe
    Daily News UC Berkeley Receives CRISPR Patent in Europe

    The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.

  2. DNA Replication Errors Contribute to Cancer Risk
  3. Should Healthy People Have Their Exomes Sequenced?
    Daily News Should Healthy People Have Their Exomes Sequenced?

    With its announced launch of a whole-exome sequencing service for apparently healthy individuals, Ambry Genetics is the latest company to enter this growing market. But whether these services are useful for most people remains up for debate.  

  4. Rethinking a Cancer Drug Target
    Daily News Rethinking a Cancer Drug Target

    The results of a CRISPR-Cas9 study suggest that MELK—a protein thought to play a critical role in cancer—is not necessary for cancer cell survival.

Business Birmingham